The variety of targets increased in 2019 and 2020, including IL-36 (all four trials for psoriasis), IL-23 alone (two for psoriasis), IL-2 (1, bullous pemphigoid), IL-5 (1, bullous pemphigoid), GLP-1(1, psoriasis), complement component 5a (C5a, 1, hidradenitis suppurativa), and immunoglobulin E (IgE, 1, CSU). Here, IL5 is linked to hidradenitis suppurativa.